StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the medical equipment provider’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a research report on Friday.
Read Our Latest Stock Report on AEMD
Aethlon Medical Stock Down 2.8 %
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Stock Average Calculator
- Applied Materials Market Capitulates: Now is the Time to Buy
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.